12 completed, 2 terminated, 1 unknown. 11 Phase 1, 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 9, Terminated 2 |
| Phase 2 | 6 | Completed 4, Terminated 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow laromustine: new trials by email Literature Review of laromustine trials Research Report on laromustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia amsacrine, busulfan, cytarabine - Leukemia | Phase 1 / Phase 2 | Completed | Institut Paoli-Calmettes | 135 | 2009-01-01 | 2011-05-13 |
| Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine Laromustine (VNP40101M) and Ara-C - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 / Phase 2 | Terminated | Viron Therapeutics Inc | 25 | 2008-03-01 | 2019-01-28 |
| VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma CLORETAZINE, temozolomide - Brain and Central Nervous System Tumors | Phase 1 | Terminated | Northwestern University | 14 | 2007-08-01 | 2011-08-26 |
| Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies Cloretazine, Fludarabine - Hematologic Malignancies | Phase 1 | Completed | M.D. Anderson Cancer Center | 5 | 2007-08-01 | 2012-07-31 |
| VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia cytarabine, laromustine - Leukemia | Phase 2 | Unknown | Vion Pharmaceuticals | 85 | 2006-05-01 | 2014-01-10 |
| VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia hydroxyurea, laromustine - Leukemia, Myelodysplastic Syndromes | Phase 2 | Completed | Vion Pharmaceuticals | 230 | 2005-11-01 | 2013-07-18 |
| VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer laromustine - Lung Cancer | Phase 2 | Completed | Vion Pharmaceuticals | 87 | 2005-09-01 | 2013-11-06 |
| VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders laromustine - Leukemia, Lymphoma | Phase 1 / Phase 2 | Completed | Vion Pharmaceuticals | 35 | 2005-07-01 | 2013-07-18 |
| Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia cytarabine, laromustine, placebo - Leukemia | Phase 3 | Completed | Vion Pharmaceuticals | 420 | 2005-03-01 | 2013-11-06 |
| VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors laromustine - Brain and Central Nervous System Tumors | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 42 | 2005-02-01 | 2011-06-30 |
| Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias laromustine, temozolomide - Leukemia | Phase 1 | Completed | Vion Pharmaceuticals | 25 | 2004-09-01 | 2013-07-18 |
| VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies cytarabine, laromustine - Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | Vion Pharmaceuticals | 2003-06-01 | 2013-07-18 | |
| VNP40101M in Treating Patients With Advanced or Metastatic Cancer laromustine - Lymphoma, Small Intestine Cancer | Phase 1 | Completed | Vion Pharmaceuticals | 2002-10-01 | 2013-07-18 | |
| VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome laromustine - Leukemia, Myelodysplastic Syndromes | Phase 1 | Completed | Vion Pharmaceuticals | 2002-04-01 | 2013-07-18 | |
| VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas laromustine - Lymphoma, Small Intestine Cancer | Phase 1 | Completed | Vion Pharmaceuticals | 2001-03-01 | 2013-07-18 |
Leukemia (10) · Leukemia, Myeloid, Acute (7) · Congenital Abnormalities (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Hodgkin Disease (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma (4) · Myelodysplastic Syndromes (4) · Leukemia, Myelomonocytic, Chronic (3) · Lymphoma, Large B-Cell, Diffuse (3) · Anemia, Refractory, with Excess of Blasts (2) · Astrocytoma (2) · Blast Crisis (2) · Burkitt Lymphoma (2) · Central Nervous System Neoplasms (2)
Vion Pharmaceuticals (10) · Institut Paoli-Calmettes (1) · M.D. Anderson Cancer Center (1) · Northwestern University (1) · Pediatric Brain Tumor Consortium (1) · Viron Therapeutics Inc (1)
United States (14) · France (4) · United Kingdom (3) · Belgium (1) · Canada (1) · Germany (1) · Greece (1) · Netherlands (1) · Poland (1) · Serbia (1)
Bonny L. Johnson, RN, MSN (5) · Mario Sznol, MD (4) · Francis J. Giles, MD (1) · Jeffrey Raizer, MD (1) · Norbert Vey, MD (1) · Roy B. Jones, MD, PhD (1) · Sri Gururangan, MRCP (UK) (1)
PMID 16278404, PMID 17146105, PMID 18281546, PMID 19710500, PMID 20511167